Cryoport Reports Record Results for Full Year 2020
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/23/2026
- Wall St futures muted; Mideast talks, US-China summit in focus
- Activist Jana Partners calls for Six Flags sale - WSJ
- Oil holds near two-week lows while diesel cracks hit record peak
- Meta AI agent triggers heavy selloff in banks, insurers, and travel stocks
- Exclusive: SB Energy Nasdaq IPO moving forward as planned
Cryoport (CYRX) Misses Q4 EPS by $1.21, Revenues Beat
March 1, 2021 4:52 PM ESTCryoport (NASDAQ: CYRX) reported Q4 EPS of ($1.32), $1.21 worse than the analyst estimate of ($0.11). Revenue for the quarter came in at $48.36 million versus the consensus estimate of $43.95 million.
"Our fourth quarter was a transformational quarter, furthering our strategy and strengthening our positioning for growth. Its results reflected strong performance and our continued momentum in the markets we serve, especially in Cell and Gene Therapy. We increased... More
